Altimmune earnings were -$91.1M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest ALT earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$22.6M, down 17.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ALT reported annual earnings of -$88.1M, with -7.3% growth. The next ALT earnings date is Aug 11, 2026.
On ALT's earnings call on May 19, 2026, Altimmune (NASDAQ: ALT) reported Q1 2026 earnings per share (EPS) of -$0.18, up 30.77% year over year. Total ALT earnings for the quarter were -$22.56 million. In the same quarter last year, Altimmune's earnings per share (EPS) was -$0.26.
The next ALT earnings call is Aug 11, 2026. Add ALT to your watchlist to be reminded of Altimmune's next earnings date.
Is Altimmune profitable or losing money?
As of the last Altimmune earnings report, Altimmune is currently losing money. Altimmune's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$91.08 million, a 0.93% increase year over year.
What was ALT's earnings growth in the past year?
As of Altimmune's earnings date in May 19, 2026, Altimmune's earnings has grown year over year. ALT earnings in the past year totalled -$91.08 million.
What are Altimmune's earnings expectations?
The current EPS estimate for Altimmune's earnings report in Aug 11, 2026 is -$0.17.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.